Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Net Margin (2020 - 2025)

Maravai Lifesciences Holdings has reported Net Margin over the past 6 years, most recently at 126.37% for Q4 2025.

  • Quarterly results put Net Margin at 126.37% for Q4 2025, down 4492.0% from a year ago — trailing twelve months through Dec 2025 was 124.24% (down 2407.0% YoY), and the annual figure for FY2025 was 124.24%, down 2407.0%.
  • Net Margin for Q4 2025 was 126.37% at Maravai Lifesciences Holdings, down from 108.23% in the prior quarter.
  • Over the last five years, Net Margin for MRVI hit a ceiling of 64.57% in Q2 2022 and a floor of 249.84% in Q3 2024.
  • Median Net Margin over the past 5 years was 19.96% (2023), compared with a mean of 31.28%.
  • Biggest five-year swings in Net Margin: tumbled -22726bps in 2024 and later skyrocketed 14161bps in 2025.
  • Maravai Lifesciences Holdings' Net Margin stood at 55.64% in 2021, then dropped by -23bps to 42.71% in 2022, then crashed by -447bps to 148.34% in 2023, then skyrocketed by 45bps to 81.45% in 2024, then crashed by -55bps to 126.37% in 2025.
  • The last three reported values for Net Margin were 126.37% (Q4 2025), 108.23% (Q3 2025), and 147.34% (Q2 2025) per Business Quant data.